Jochen Gaedcke

Jochen Gaedcke


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2013 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Open access
PDF file
JGJochen Gaedcke
Jochen Gaedcke
PSP. Schüler
P. Schüler
JBJ. Brinker
J. Brinker
MQM. Quintel
M. Quintel
MGM. Ghadimi
M. Ghadimi
Introduction Giant inguinoscrotal hernias are rare but still exist even in developed countries. Although accompanied by a higher perioperative mortality, an elective surgical approach should be undertaken. In critically ill patients, however, the surgical intervention requires specific demands. Methods We report a case of a 45-year-old man who was referred to the hospital after perforation of the hernia with concomitant peritonitis and sepsis. Results After initial stabilization of the patient, a subtotal colectomy and a partial small bowl resection was performed. In a second step after stabilization of organ functions, the hernia sac was resected, and the abdominal cavity was reconstructed. The patient was discharged and is doing well until today but still refuses any plastic surgery. Conclusion Resection of giant inguinoscrotal hernia is feasible even in patients being administered in an emergency setting. Especially in case of an intra-abdominal infection, intestinal resection is the therapy of choice to allow the reconstruction of the abdominal cavity. A two-step approach should be considered to allow a successful recovery.

13 February 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JGJochen Gaedcke
Jochen Gaedcke
MSMalte Sahrhage
Malte Sahrhage
MEMarcel Ebeling
Marcel Ebeling
AAAzadeh Azizian
Azadeh Azizian
FRFelix Rühlmann
Felix Rühlmann
MGMichael Ghadimi
Michael Ghadimi
Low anterior resection (LAR) and abdominoperineal resection (APR) are the two main surgical procedures after preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer. APR is associated with poorer prognosis; however existing data do not consider intensified CRT (5-Fluorouracil (5-FU)/Oxaliplatin + radiation) protocols. Clinicopathological data of patients treated with APR and LAR from the CAO/ARO/AIO-04 trial were analysed in terms of prognostic parameters and quality of life (QoL). Based on higher response rate after intensified CRT, subgroup analyses were performed. Data from n = 1173 patients were assessed. APR after preoperative CRT was associated with a significantly worse overall survival (p = 0.0056), disease-free survival (p < 0.0001) and local recurrence rate (p = 0.0047). Clinicopathological data including clinical T stage (p < 0.000001), grading (p = 0.0038), postoperative lymph node (LN) positivity (p = 0.013), and number of positive LN (p = 0.0049) significantly differed between procedures and showed higher values in APR patients. The quality of total mesorectal excision (TME) was significantly better (p < 0.0001) and complete resection rates were higher (p = 0.0022) in LAR compared to APR patients. Subgroup analyses showed worse LR rates in APR patients after standard CRT (5-FU mono and radiation) but not after intensified CRT. After 3 years, role functioning (p = 0.019) and physical functioning (p = 0.001) had a slightly poorer outcome in APR patients. The poorer prognosis of patients undergoing APR for locally advanced rectal cancer may be explained by clinicopathological characteristics. Intensified CRT may compensate for the higher risk of LR after APR in patients with worse TME quality. QoL in APR patients was comparable to LAR patients.

4 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MLMartin Leu
Martin Leu
TRTheresa Riebeling
Theresa Riebeling
LDLeif Hendrik Dröge
Leif Hendrik Dröge
LHLaura Hubert
Laura Hubert
Manuel GuhlichManuel Guhlich
Manuel Guhlich
Markus SchirmerMarkus Schirmer
Markus Schirmer
Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer.

23 January 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
FRFelix Rühlmann
Felix Rühlmann
AAAzadeh Azizian
Azadeh Azizian
CMChristian Moosmann
Christian Moosmann
MBMarkus Bernhardt
Markus Bernhardt
JKJan Keck
Jan Keck
JGJochen Gaedcke
Jochen Gaedcke
Background: Postoperative liver failure (PLF) is a severe complication after major liver resection (MLR). To increase the safety of patients, clinical bedside tests are of great importance. However, limitations of their applicability and validity impair their value. Methods: Preoperative measurements of the liver maximum capacity (LiMAx) were performed in n = 40 patients, who underwent MLR (≥3 segments). Matched postoperative LiMAx was measured in n = 21 patients. Liver function was compared between pretreated patients (n = 11 with portal vein embolisation (PVE) and n = 19 patients with preoperative chemotherapy) and therapy naïve patients. The LiMAx values were compared with liver-specific blood parameters and volumetric analysis. Results: In total, n = 40 patients were enrolled in this study. The majority of patients (n = 33; 82.5%) had high preoperative LiMAx values (>315 µg/kg/h), while only seven patients (17.5%) had medium values (140–315 µg/kg/h), and none of the patients had low values ( 0.05). The preoperative LiMAx values were significantly higher than the matched postoperative values on postoperative day 1 (p < 0.0001). A comparison between the expected and measured postoperative LiMAx showed a difference (≥10%) in 7 out of 13 patients (53.8%). After an initial postoperative decrease in the LiMAx, the patients without complications (n = 12) showed a continuous increase until 14 days after surgery. In the patients with postoperative complications, a decrease in the LiMAx was associated with a prolonged recovery. Conclusions: For patients undergoing MLR within the 0.5% rule, which is the clinical gold standard, the LiMAx values do not offer any additional information. Additionally, the LiMAx may have reflected liver function, but it did not deliver additional information regarding postoperative liver recovery. The clinical use of LiMAx might be relevant in selected patients beyond the 0.5% rule.

15 August 2012 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
MGM Grade
M Grade
MSM Spitzner
M Spitzner
BRB Roesler
B Roesler
CBC Bielfeld
C Bielfeld
GEG Emons
G Emons
MGM Ghadimi
M Ghadimi
Aims: Resistance to preoperative chemoradiotherapy represents a major clinical problem in the treatment of patients with locally advanced rectal cancer. Therefore, the identification of molecular biomarkers that differentiate responsive and resistant tumors is exceedingly important, because this may lead to the identification of novel molecular targets whose modification could be harnessed to sensitize a priori resistant tumors to multimodal treatment. Materials/methods: We recently established an in vitro model for 5-FU based chemoradiotherapy, and correlated differences in treatment sensitivity of 12 colorectal cancer cell lines with pretherapeutic gene expression profiles. One gene the expression of which correlated positively with treatment resistance was the signal transducer and activator of transcription 3, STAT3. To test the functional relevance of this observation, we first determined STAT3 mRNA and protein expression levels in all cell lines. Next, we established doxycycline-inducible stable shRNA single-cell clone (SCC) populations. Successful silencing of STAT3 was detected by Western blot analysis. The induced SCCs were treated with 3µM 5-FU, and subsequently exposed to 0, 1, 2, 4, 6, and 8Gy of X-rays. In addition, STAT3 was inhibited using two different siRNAs, and a small-molecular inhibitor (STATTIC). Results: STAT3 was significantly overexpressed in resistant cells. In SW480 and SW837 cells, both shRNA- and siRNA-mediated silencing as well as STATTIC-induced inhibition of STAT3-phosphorylation resulted in a significantly increased chemoradiosensitivity, with dose-reduction factors of 1.8 to 2. Conclusion: These results highlight the potential relevance of STAT3 as a novel molecular target to sensitize a priori resistant tumor cells to chemoradiotherapy.

16 August 2013 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
PJPyj Jo
Pyj Jo
JSJ Salendo
J Salendo
JKJ Kitz
J Kitz
LCLc Conradi
Lc Conradi
AAA Azizian
A Azizian
JGJochen Gaedcke
Jochen Gaedcke
Einleitung: Beim kolorektalen Karzinom ist die zielgerichtete Therapie gegen den Epidermal Growth Factor Receptor (EGFR), speziell in der metastasierten Situation, eine etablierte Therapieoption bei Tumoren mit einem bekannten KRAS Wildtyp (WT) Status. Vor Beginn der Therapie ist daher die Bestimmung des KRAS Status von großer Bedeutung. Im kolorektalen Karzinom ist ein bestimmter Grad an KRAS Mutations-Heterogenität bekannt. Für das neoadjuvant behandelte Rektumkarzinom ist zu klären, ob der prä- und posttherapeutische KRAS Mutationsstatus vergleichbar ist (intertumorale Heterogenität). Ziele: Ziel dieser Arbeit war die Rate der Übereinstimmung für den KRAS Mutationsstatus bei Patienten mit neoadjuvant therapierten lokal fortgeschrittenen Rektumkarzinomen zu untersuchen (Intertumorale KRAS Heterogenität). Daher wurde Tumorgewebe von 47 Patienten analysiert mit insgesamt 114 präoperativen Biopsien und 85 Tumorblöcken aus Rektumresektaten. Darüberhinaus wurde die intratumorale KRAS Heterogenität in prätherapeutischen Biopsien von 34 (durchschnittlich 3.0 Biopsien/Patient) und in Rektumresektaten von 12 Patienten (durchschnittlich 4.2 Tumorblöcke/Patienten) analysiert. Methodik: Für die KRAS Mutationsbestimmung wurde für das KRAS Gen (Codon 12, 13, 61 und 146) die Primer Extensions Methode eingesetzt. Ergebnis: Der Vergleich zwischen dem prä- und posttherapeutischen KRAS Mutationsstatus offenbarte eine Diskrepanz in 6 von 47 Patienten (12,8%). Eine Intratumorale KRAS Heterogenität in prätherapeutischen Biopsien wurde in nur einem Patienten nachgewiesen (Wildtyp vs. G12V). In den Rektumresektaten zeigte sich die intratumorale Heterogenität in 6 Patienten (50%). Schlussfolgerung: Schlussfolgernd ist eine KRAS Mutations-Heterogenität in posttherapeutischen Tumoren nicht zu vernachlässigen. Bei der klinischen Entscheidung über den Einsatz eines EGFR-Antikörpers sollte in Abhängigkeit vom residuellen Tumorgrad die Bestimmung des KRAS Status in mehr als nur einem Tumorblock durchgeführt werden.